

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of isolating one or more target compounds from other component(s) of a liquid by at least two chromatographic steps comprising:

contacting the liquid, in any sequence of order, with an affinity chromatography matrix and an ion-exchange and/or hydrophobic interaction chromatography matrix to provide interactions between the target compound and the matrices, wherein the contacting with at least one of the matrices takes place in the presence of at least one non-ionic polyether at a concentration of 4-8%; and

obtaining the target compound(s) in a separate fraction from the last chromatographic step,

wherein the dynamic binding capacity in one of the steps is increased by at least 1.5 times compared to a corresponding step without the addition of said non-ionic polyether.

Claim 2 (previously presented): The method of claim 1, wherein the target compound(s) are adsorbed to one or more of the chromatography matrices.

Claim 3 (previously presented): The method of claim 2, wherein the adsorbed target compound(s) are released by contacting the chromatography matrix with an eluent.

Claim 4 (previously presented): The method of claim 1, including two or more consecutive ion-exchange chromatography steps.

Claim 5 (previously presented): The method of claim 1, including an affinity chromatography step followed by an ion-exchange chromatography step.

Claim 6 (previously presented): The method of claim 1, comprising an ion-exchange chromatography step followed by a hydrophobic interaction chromatography step.

Claim 7 (previously presented): The method of claim 1, including three chromatographic steps.

Claim 8 (previously presented): The method of claim 1, wherein the first chromatography step is performed in the presence of a non-ionic polyether.

Claim 9 (previously presented): The method of claim 1, wherein at least two steps are performed in the presence of a non-ionic polyether.

Claim 10 (previously presented): The method of claim 1, wherein the non-ionic polyether is poly(ethylene glycol) (PEG).

Claim 11 (previously presented): The method of claim 1, wherein the target compound is an antibody or an antibody compound.

Claim 12 (previously presented): The method of claim 1, including an affinity step using a matrix comprised of protein ligands immobilised to porous carriers.

Claim 13 (previously presented): The method of claim 12, wherein the protein ligands includes one or more of the immunoglobulin-binding domains of Protein A.

Claim 14 (previously presented): The method of claim 12, wherein the carriers are comprised of cross-linked polysaccharide particles.

Claim 15 (previously presented): The method of claim 1, including an ion-exchange step using a matrix comprised of ligands with charged groups, which ligands have been immobilised to a carrier via extenders.

Claim 16 (previously presented): The method of claim 15, wherein the extenders are provided by coating the carrier surfaces with dextran.

Claim 17 (previously presented): The method of claim 15, wherein the carriers are comprised of porous cross-linked polysaccharide particles.

Claims 18-28 (cancelled)

Claim 29 (previously presented): The method of claim 1, wherein the at least one non-ionic polyether has a molecular weight between 5000 and 15000.

Claim 30 (previously presented): The method of claim 29, wherein the at least one non-ionic polyether is poly(ethylene glycol) (PEG).

Claims 31-32 (cancelled)